{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T05:09:27Z","timestamp":1782364167217,"version":"3.54.5"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T00:00:00Z","timestamp":1529366400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Regeneron Pharmaceuticals, Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13075-018-1614-z","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T07:31:38Z","timestamp":1529393498000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab  monotherapy in patients with rheumatoid arthritis"],"prefix":"10.1186","volume":"20","author":[{"given":"Vibeke","family":"Strand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare W. J.","family":"Proudfoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh-I","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Reaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Guillonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"van Adelsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin K.","family":"Mangan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"van Hoogstraten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd R.","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,19]]},"reference":[{"key":"1614_CR1","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1186\/s13075-014-0470-8","volume":"16","author":"HG Schaible","year":"2014","unstructured":"Schaible HG. Nociceptive neurons detect cytokines in arthritis. Arthritis Res Ther. 2014;16:470.","journal-title":"Arthritis Res Ther."},{"key":"1614_CR2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/rheumatology\/38.3.202","volume":"38","author":"G Steiner","year":"1999","unstructured":"Steiner G, Tohidast-Akrad M, Witzmann G, Vesely M, Studnicka-Benke A, Gal A, Kunaver M, Zenz P, Smolen JS. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford). 1999;38:202\u201313.","journal-title":"Rheumatology (Oxford)"},{"key":"1614_CR3","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1007\/s00296-006-0143-2","volume":"26","author":"T Matsumoto","year":"2006","unstructured":"Matsumoto T, Tsurumoto T, Shindo H. Interleukin-6 levels in synovial fluids of patients with rheumatoid arthritis correlated with the infiltration of inflammatory cells in synovial membrane. Rheumatol Int. 2006;26:1096\u2013100.","journal-title":"Rheumatol Int"},{"key":"1614_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/00124743-199504000-00006","volume":"1","author":"E Sugiyama","year":"1995","unstructured":"Sugiyama E, Kuroda A, Hori F, Hori T, Taki H, Arai N, Kobayashi M. Serum interleukin-6 level is a sensitive parameter of disease activity in rheumatoid arthritis. J Clin Rheumatol. 1995;1:93\u20138.","journal-title":"J Clin Rheumatol"},{"key":"1614_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/rheumatology\/kep329","volume":"49","author":"JM Dayer","year":"2010","unstructured":"Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford). 2010;49:15\u201324.","journal-title":"Rheumatology (Oxford)"},{"key":"1614_CR6","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/art.39093","volume":"67","author":"MC Genovese","year":"2015","unstructured":"Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, Rohane P, van Hoogstraten H, Garg A, Fan C, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67:1424\u201337.","journal-title":"Arthritis Rheumatol"},{"key":"1614_CR7","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1136\/ard.2008.093690","volume":"68","author":"C Salliot","year":"2009","unstructured":"Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis. 2009;68:1100\u20134.","journal-title":"Ann Rheum Dis"},{"key":"1614_CR8","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10067-014-2546-x","volume":"33","author":"E Nikiphorou","year":"2014","unstructured":"Nikiphorou E, Negoescu A, Fitzpatrick JD, Goudie CT, Badcock A, Ostor AJ, Malaviya AP. Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort. Clin Rheumatol. 2014;33:609\u201314.","journal-title":"Clin Rheumatol"},{"key":"1614_CR9","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.3899\/jrheum.080889","volume":"36","author":"SJ Lee","year":"2009","unstructured":"Lee SJ, Chang H, Yazici Y, Greenberg JD, Kremer JM, Kavanaugh A. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study. J Rheumatol. 2009;36:1611\u20137.","journal-title":"J Rheumatol"},{"key":"1614_CR10","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1136\/ard.2010.139774","volume":"70","author":"MM Soliman","year":"2011","unstructured":"Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70:583\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1614_CR11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13075-016-1096-9","volume":"18","author":"V Strand","year":"2016","unstructured":"Strand V, Kosinski M, Chen CI, Joseph G, Rendas-Baum R, Graham NM, van Hoogstraten H, Bayliss M, Fan C, Huizinga T, et al. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Arthritis Res Ther. 2016;18:198.","journal-title":"Arthritis Res Ther."},{"key":"1614_CR12","unstructured":"Fleischmann R, Castelar-Pinheiro G, Brzezicki J, Hrycaj P, Lin Y, van Adelsberg J, Graham N, van Hoogstraten H, Bauer D, Burmester G. Efficacy and safety of sarilumab in combination with Csdmards in patients with active rheumatoid arthritis who were inadequate responders or intolerant of anti-TNF therapy: results from a phase 3 study [abstract 970]. Arthritis Rheumatol. 2015;67(Suppl 10)."},{"key":"1614_CR13","doi-asserted-by":"publisher","first-page":"e000416","DOI":"10.1136\/rmdopen-2016-000416","volume":"3","author":"V Strand","year":"2017","unstructured":"Strand V, Reaney M, Chen CI, Proudfoot CW, Guillonneau S, Bauer D, Mangan E, Graham NM, van Hoogstraten H, Lin Y, et al. Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response\/intolerance to tumour necrosis factor inhibitors. RMD Open. 2017;3:e000416.","journal-title":"RMD Open"},{"key":"1614_CR14","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","volume":"76","author":"G Burmester","year":"2017","unstructured":"Burmester G, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NMH, van Hoogstraten H, Bauer D, Ignacio Vargas J, Bong Lee E. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017;76:840\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1614_CR15","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/acr.22824","volume":"68","author":"K van der Elst","year":"2016","unstructured":"van der Elst K, Meyfroidt S, De Cock D, De Groef A, Binnard E, Moons P, Verschueren P, Westhovens R. Unraveling patient-preferred health and treatment outcomes in early rheumatoid arthritis: a longitudinal qualitative study. Arthritis Care Res (Hoboken). 2016;68:1278\u201387.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1614_CR16","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1136\/ard.2008.100271","volume":"68","author":"L Gossec","year":"2009","unstructured":"Gossec L, Dougados M, Rincheval N, Balanescu A, Boumpas DT, Canadelo S, Carmona L, Daures JP, de Wit M, Dijkmans BA, et al. Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis. 2009;68:1680\u20135.","journal-title":"Ann Rheum Dis"},{"key":"1614_CR17","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/rheumatology\/ket416","volume":"53","author":"CA Flurey","year":"2014","unstructured":"Flurey CA, Morris M, Richards P, Hughes R, Hewlett S. It\u2019s like a juggling act: rheumatoid arthritis patient perspectives on daily life and flare while on current treatment regimes. Rheumatology (Oxford). 2014;53:696\u2013703.","journal-title":"Rheumatology (Oxford)"},{"key":"1614_CR18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.semarthrit.2013.08.004","volume":"43","author":"M Cutolo","year":"2014","unstructured":"Cutolo M, Kitas GD, van Riel PL. Burden of disease in treated rheumatoid arthritis patients: going beyond the joint. Semin Arthritis Rheum. 2014;43:479\u201388.","journal-title":"Semin Arthritis Rheum"},{"key":"1614_CR19","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1007\/s10067-014-2667-2","volume":"33","author":"G Ostlund","year":"2014","unstructured":"Ostlund G, Bjork M, Thyberg I, Thyberg M, Valtersson E, Stenstrom B, Sverker A. Emotions related to participation restrictions as experienced by patients with early rheumatoid arthritis: a qualitative interview study (the Swedish TIRA project). Clin Rheumatol. 2014;33:1403\u201313.","journal-title":"Clin Rheumatol"},{"key":"1614_CR20","doi-asserted-by":"publisher","first-page":"e000019","DOI":"10.1136\/rmdopen-2014-000019","volume":"1","author":"L Gossec","year":"2015","unstructured":"Gossec L, Dougados M, Dixon W. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open. 2015;1:e000019.","journal-title":"RMD Open."},{"key":"1614_CR21","volume-title":"Guidance for Industry: Patient-reported outcome measures: use in medical product development to support labeling claims","author":"Food and Drug Administration","year":"2009","unstructured":"Food and Drug Administration. Guidance for Industry: Patient-reported outcome measures: use in medical product development to support labeling claims. 2009. \n                    https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm193282.pdf\n                    \n                  . Accessed 23 Feb 2017."},{"key":"1614_CR22","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/art.1780360601","volume":"36","author":"DT Felson","year":"1993","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum. 1993;36:729\u201340.","journal-title":"Arthritis Rheum"},{"key":"1614_CR23","unstructured":"Ware Jr JE, Kosinski M, Bjorner JB, Turner-Bowker D, Maruish ME. User\u2019s manual for the SF-36v2\u2122 Health Survey. 2nd ed. Lincoln, RI: Quality Metric; 2007."},{"key":"1614_CR24","first-page":"811","volume":"32","author":"D Cella","year":"2005","unstructured":"Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005;32:811\u20139.","journal-title":"J Rheumatol"},{"key":"1614_CR25","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0895-4356(97)00051-6","volume":"50","author":"TP Vliet Vlieland","year":"1997","unstructured":"Vliet Vlieland TP, Zwinderman AH, Breedveld FC, Hazes JM. Measurement of morning stiffness in rheumatoid arthritis clinical trials. J Clin Epidemiol. 1997;50:757\u201363.","journal-title":"J Clin Epidemiol"},{"key":"1614_CR26","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1136\/ard.2010.142901","volume":"70","author":"L Gossec","year":"2011","unstructured":"Gossec L, Paternotte S, Aanerud GJ, Balanescu A, Boumpas DT, Carmona L, de Wit M, Dijkmans BA, Dougados M, Englbrecht M, et al. Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis. 2011;70:935\u201342.","journal-title":"Ann Rheum Dis"},{"key":"1614_CR27","doi-asserted-by":"publisher","first-page":"R73","DOI":"10.1186\/ar2702","volume":"11","author":"JT Osterhaus","year":"2009","unstructured":"Osterhaus JT, Purcaru O, Richard L. Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA). Arthritis Res Ther. 2009;11:R73.","journal-title":"Arthritis Res Ther."},{"key":"1614_CR28","first-page":"557","volume":"20","author":"GA Wells","year":"1993","unstructured":"Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient\u2019s perspective. J Rheumatol. 1993;20:557\u201360.","journal-title":"J Rheumatol"},{"key":"1614_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","volume":"73","author":"M Schiff","year":"2014","unstructured":"Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, Maldonado M, Fleischmann R. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73:86\u201394.","journal-title":"Ann Rheum Dis"},{"key":"1614_CR30","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/art.30158","volume":"63","author":"JM Kremer","year":"2011","unstructured":"Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, Ambs P, Fleischmann R. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011;63:609\u201321.","journal-title":"Arthritis Rheum"},{"key":"1614_CR31","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.3899\/jrheum.110392","volume":"38","author":"V Strand","year":"2011","unstructured":"Strand V, Boers M, Idzerda L, Kirwan JR, Kvien TK, Tugwell PS, Dougados M. It\u2019s good to feel better but it\u2019s better to feel good and even better to feel good as soon as possible for as long as possible: response criteria and the importance of change at OMERACT 10. J Rheumatol. 2011;38:1720\u20137.","journal-title":"J Rheumatol"},{"key":"1614_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","volume":"9","author":"RH Dworkin","year":"2008","unstructured":"Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105\u201321.","journal-title":"J Pain"},{"key":"1614_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2165\/00019053-200422001-00004","volume":"22","author":"DP Lubeck","year":"2004","unstructured":"Lubeck DP. Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. PharmacoEconomics. 2004;22:27\u201338.","journal-title":"PharmacoEconomics"},{"key":"1614_CR34","doi-asserted-by":"publisher","first-page":"R129","DOI":"10.1186\/ar3859","volume":"14","author":"M Dougados","year":"2012","unstructured":"Dougados M, Brault Y, Logeart I, van der Heijde D, Gossec L, Kvien T. Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID). Arthritis Res Ther. 2012;14:R129.","journal-title":"Arthritis Res Ther."},{"key":"1614_CR35","doi-asserted-by":"publisher","first-page":"R505","DOI":"10.1186\/ar1220","volume":"6","author":"E Krishnan","year":"2004","unstructured":"Krishnan E, Tugwell P, Fries JF. Percentile benchmarks in patients with rheumatoid arthritis: Health Assessment Questionnaire as a quality indicator (QI). Arthritis Res Ther. 2004;6:R505\u201313.","journal-title":"Arthritis Res Ther"},{"key":"1614_CR36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1477-7525-1-79","volume":"1","author":"K Webster","year":"2003","unstructured":"Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79.","journal-title":"Health Qual Life Outcomes"},{"key":"1614_CR37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3899\/jrheum.101161","volume":"39","author":"V Strand","year":"2012","unstructured":"Strand V, Rentz AM, Cifaldi MA, Chen N, Roy S, Revicki D. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study. J Rheumatol. 2012;39:63\u201372.","journal-title":"J Rheumatol"},{"key":"1614_CR38","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","volume":"381","author":"C Gabay","year":"2013","unstructured":"Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, Klearman M, Musselman D, Agarwal S, Green J, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381:1541\u201350.","journal-title":"Lancet"},{"key":"1614_CR39","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1185\/03007995.2014.896328","volume":"30","author":"R Rendas-Baum","year":"2014","unstructured":"Rendas-Baum R, Bayliss M, Kosinski M, Raju A, Zwillich SH, Wallenstein GV, Koncz T. Measuring the effect of therapy in rheumatoid arthritis clinical trials from the patient\u2019s perspective. Curr Med Res Opin. 2014;30:1391\u2013403.","journal-title":"Curr Med Res Opin"},{"key":"1614_CR40","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/art.39678","volume":"68","author":"JR Kirwan","year":"2016","unstructured":"Kirwan JR, de Wit MP, Bingham CO 3rd, Leong A, Richards P, Tugwell P, Voshaar M, Commentary GL. Patients as partners: building on the experience of outcome measures in rheumatology. Arthritis Rheumatol. 2016;68:1334\u20136.","journal-title":"Arthritis Rheumatol."},{"key":"1614_CR41","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3109\/03009742.2011.566434","volume":"125","author":"JA da Silva","year":"2011","unstructured":"da Silva JA, Phillips S, Buttgereit F. Impact of impaired morning function on the lives and well-being of patients with rheumatoid arthritis. Scand J Rheumatol Suppl. 2011;125:6\u201311.","journal-title":"Scand J Rheumatol Suppl"},{"key":"1614_CR42","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/rheumatology\/kem317","volume":"47","author":"T Mittendorf","year":"2008","unstructured":"Mittendorf T, Dietz B, Sterz R, Cifaldi MA, Kupper H, von der Schulenburg JM. Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient\u2019s perspective. Rheumatology (Oxford). 2008;47:188\u201393.","journal-title":"Rheumatology (Oxford)"},{"key":"1614_CR43","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3109\/14397595.2013.843760","volume":"24","author":"T Koike","year":"2014","unstructured":"Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, Yamanaka H, Haruna S, Ushida N, Kawana K, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients. Mod Rheumatol. 2014;24:390\u20138.","journal-title":"Mod Rheumatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1614-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-018-1614-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1614-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T07:44:35Z","timestamp":1568965475000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-018-1614-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,19]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1614"],"URL":"https:\/\/doi.org\/10.1186\/s13075-018-1614-z","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,19]]},"assertion":[{"value":"6 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol received approval from the institutional review board and independent ethics committee of the investigational centers and was performed in accordance with the Declaration of Helsinki. All patients provided written consent prior to study participation, and the trial was conducted in compliance with institutional review board regulations, the International Conference on Harmonisation Guidelines for Good Clinical Practice, and the Declaration of Helsinki. The specific ethical bodies that approved study are as follows: Comit\u00e9 de \u00c9tica Cient\u00edfico, S.S.M. Oriente, Chile; Eticka komise, Revmatologickeho ustavu, Czech Republic; EK FN Kr\u00e1lovsk\u00e9, Vinohrady, FN Kralovske Vinohrady, Czech Republic; Eticka komise, Uherskohradistske nemocnice, a.s., Czech Republic; Ethik-Kommission des Landes Berlin, Landesamt f\u00fcr Gesundheit und Soziales, Berlin, Germany; Medical Research Council, Ethics Committee for Clinical Pharmacology, Hungary; Ethics Committee of Tel Aviv, Sourasky Medical Center, Israel; EC of Sheba Medical Center, The Chaim Sheba Medical Center, Israel; Ethics Committee of Carmel Medical Center, Israel; Seoul National University Hospital, Republic of Korea; Eulji University Hospital, Republic of Korea; Keimyung University, Dongsan Medical Center, Republic of Korea; CE de la asociaci\u00f3n ben\u00e9fica Prisma Carlos Gonzales, Peru; Komisja Bioetyczna przy Okregowej Radzie Lekarskiej WIL, Poland; National Bioethics Committee of Medical Product and Medical Devices, Romania; LEC of the Scientific Research Institute of Rheumatology, Russian Federation; Ethics Board at Ministry of Health of the Russian Federation, Russian Federation; LEC of the Kemerovo State Medical Academy, Russian Federation; LEC of the Saintpetersburg I.I. Dzhanelidze Research Institute, Russian Federation; LEC of Saratov Regional Clinical Hospital, Russian Federation; LEC of \u2018Applied Medicine\u2019, Russian Federation; LEC of the Moscow City Hospital n.a. S. P. Botkin, Russian Federation; LEC of the City Clinical Hospital n.a. M.E. Zhadkevich, Russian Federation; Pharma Ethics (Pty) Ltd., South Africa; CEIC Corporaci\u00f3 Sanit\u00e0ria del Parc Taul\u00ed, Spain; LEC of the Regional Clinical Hospital n.a. N.I. Pyrogov, Ukraine; LEC of Consultative Diagnostic Center of Pechersky District, Ukraine; LEC of the Ivano-Frankivsk Regional Clinical Hospital, Ukraine; LEC of Lutsk Regional Hospital, Ukraine; LEC of Vinnytsya City Clinical Hospital #1, Ukraine; LEC of Lviv Regional Clinical Diagnostic Center, Ukraine; LEC Kyiv City Clinical Hospital #3, Ukraine; LEC of MIHC Regional Clinical Hospital, Ukraine; LEC of Poltava Regional Clinical Hospital n.a. Sklyfosofsky, Ukraine; NRES Committee London \u2013 London Bridge National Research Ethics Service, United Kingdom; Chesapeake IRB, United States; Comit\u00e9 de Protection des Personnes Est III H\u00f4pital de Brabois, France; Ethics Committee of Bnei Zion Medical Center Bnei Zion, Israel; Ethics Committee of Rambam Medical Center, Israel; Ajou University Hospital, Republic of Korea; Chungnam National University Hospital, Republic of Korea; Chosun University Hospital, Republic of Korea; Dong-A University Hospital, Republic of Korea; Wits Human Research EC, South Africa; Dartmouth Medical School IRB, United States.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"VS is a consultant for AbbVie, Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Celltrion, Corrona, Crescendo, Genentech\/Roche, GSK, Janssen, Eli Lilly & Co., Merck, Novartis, Pfizer, Regeneron, Samsung, Sandoz, Sanofi, and UCB. LG is a member of an institution that received research funding for the present study; a consultant for AbbVie, BMS, Genentech\/Roche, Janssen, Eli Lilly & Co., Novartis, Pfizer, and UCB; and a member of the executive committee of the Outcome Measures in Rheumatology initiative. GRB is a member of an institution that received research funding from Sanofi and Regeneron Pharmaceuticals, Inc., for the present study. CWJP, SG, YL, HvH, and MR are employees of and shareholders in Sanofi. TK, CIC, and JvA are employees of and shareholders in Regeneron Pharmaceuticals, Inc. EKM is a shareholder of Pfizer Inc., and Regeneron Pharmaceuticals, Inc., and an employee of Regeneron Pharmaceuticals, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"129"}}